AT&T to Release First-Quarter 2024 Earnings April 24
DALLAS, Feb. 23, 2024 /PRNewswire/ -- We will release our first-quarter 2024 results on Wednesday, April 24, and webcast a conference call to discuss results.
Key Takeaways:
AT&T will release its first-quarter 2024 results on April 24
AT&T will webcast a conference call to discuss results
AT&T* (NYSE:T) will release its first-quarter 2024 results before the New York Stock Exchange opens on Wednesday, April 24, 2024. The company's earnings release and related materials will be available at AT&T Investor Relations.
At 8:30 a.m. ET the same day, AT&T will host a conference call to discuss the results. A live webcast of the call will be available at AT&T Investor Relations, and the webcast replay and transcript will be available following the call.
*About AT&T
We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 140+ years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com.
Elbit Systems Ltd. ("Elbit Systems" or the "Company") announced today that it was awarded an initial contract of approximately $37 million to supply Iron Fist Active Protection Systems (APS) to General Dynamics Ordnance and Tactical Systems...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...